Evidence map›Paper›PMID 32861825›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020

A call for strengthened evidence on targeted, non-pharmaceutical interventions against COVID-19 for the protection of vulnerable individuals in sub-Saharan Africa.

Robert Colebunders, Joseph Nelson Siewe Fodjo, Guido Vanham, Rafael Van den Bergh

Abstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Robert ColebundersGlobal Health Institute, University of Antwerp, Gouverneur Kinsbergen Centrum, Doornstraat 331, 2610 Antwerp, Belgium. Electronic address: robert.colebunders@uantwerpen.be.
Joseph Nelson Siewe FodjoGlobal Health Institute, University of Antwerp, Gouverneur Kinsbergen Centrum, Doornstraat 331, 2610 Antwerp, Belgium. Electronic address: JosephNelson.SieweFodjo@uantwerpen.be.
Guido VanhamDepartment of Biomedical Science, University of Antwerp, Campus drie Eiken, 2610 Antwerp, Belgium. Electronic address: GVanham@ext.itg.be.
Rafael Van den BerghGlobal Health Institute, University of Antwerp, Gouverneur Kinsbergen Centrum, Doornstraat 331, 2610 Antwerp, Belgium. Electronic address: rafael.vandenbergh@uantwerpen.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the easing of lockdown measures in many sub-Saharan African countries, coronavirus disease 2019 (COVID-19) cases have been on the rise. As the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, may be difficult to stop in these settings, we propose that the existing COVID-19 prevention strategies aimed at reducing overall transmission are complemented with more targeted strategies to protect people at risk of severe COVID-19 disease. We suggest investigating the feasibility, acceptability, and efficacy of distributing COVID-19 prevention kits to households with persons at increased risk of severe COVID-19 disease.

Indexed as

BetacoronavirusAfrica South of the SaharaCoronavirus InfectionsCOVID-19Delivery of Health CareHumansPandemicsPneumonia, ViralSARS-CoV-2COVID-19MortalityPreventionRisk factorsSub-Saharan AfricaTransmission

Identifiers

PMID32861825
PMCPMC7451006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.